Brief: Medivir: Positive Data From Completed Phase Ia Study With MIV-818 In Patients With Advanced Liver Cancer
02/03/2020 07:36
March 2 (Reuters) - Medivir AB MVIRb.ST :
* MEDIVIR PRESENTS POSITIVE DATA FROM THE COMPLETED PHASE IA
STUDY
WITH MIV-818 IN PATIENTS WITH ADVANCED LIVER CANCER
* PRIMARY OBJECTIVE OF PHASE IA STUDY WAS TO EVALUATE SAFETY
AND
TOLERABILITY OF MIV-818 IN LIVER CANCER PATIENTS
* A TOTAL OF NINE PATIENTS WITH ADVANCED DISEASE WERE
INCLUDED:
SIX PATIENTS WITH METASTATIC LIVER CANCER, TWO WITH
HEPATOCELLULAR CARCINOMA AND ONE WITH INTRAHEPATIC
CHOLANGIOCARCINOMA
* PHARMACOKINETIC ANALYSIS SHOWED THAT PATIENTS WERE EXPOSED
ONLY
TO LOW LEVELS OF MIV-818 AND TROXACITABINE OUTSIDE OF LIVER,
PROVIDING EXPERIMENTAL SUPPORT FOR MIV-818'S LIVER TARGETING
* ADVERSE EVENTS WERE MAINLY MILD AND MORE SERIOUS SIDE
EFFECTS
OBSERVED WERE REVERSIBLE
* BASED ON AN INDEPENDENT EXPERT ANALYSIS OF LIVER TUMOR
GROWTH,
FIVE OF NINE PATIENTS WERE ASSESSED TO HAVE STABLE LIVER DISEASE
AFTER TREATMENT
Source text for Eikon: ID:nWkr7H3tZ3
Further company coverage: MVIRb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))